Get the Stockscreener App
1.27
12.39%
0.14
Rein Therapeutics Inc stock is traded at $1.27, with a volume of 39,885.
It is up +12.39% in the last 24 hours and down -7.97% over the past month.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
See More
Previous Close:
$1.13
Open:
$1.13
24h Volume:
39,885
Relative Volume:
1.00
Market Cap:
$29.27M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+6.37%
1M Performance:
-7.97%
6M Performance:
-52.96%
1Y Performance:
+0.00%
1-Day Range:
$1.11
$1.30
1-Week Range:
$1.06
$1.30
52-Week Range:
$1.04
$3.50
Rein Therapeutics Inc Stock (RNTX) Company Profile
Name
Rein Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN
Compare RNTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNTX
Rein Therapeutics Inc
|
1.27 | 26.04M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Rein Therapeutics Inc Stock (RNTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Rein Therapeutics Inc Stock (RNTX) Latest News
Is Rein Therapeutics Inc. stock reversal real or fakeQuarterly Trade Summary & High Yield Stock Recommendations - Newser
Is Rein Therapeutics Inc. Forming a Bottom PatternJuly 2025 Earnings & Weekly Top Stock Performers List - kangso.co.kr
Market reaction to Rein Therapeutics Inc.’s recent news2025 Investor Takeaways & Real-Time Sentiment Analysis - Newser
Rein Therapeutics Inc. stock daily chart insightsJuly 2025 Retail & Risk Controlled Stock Pick Alerts - Newser
What the charts say about Rein Therapeutics Inc. today2025 Technical Patterns & Free Expert Approved Momentum Trade Ideas - Newser
Rein Therapeutics (NASDAQ:RNTX) Given “Hold” Rating at Brookline Capital Management - Defense World
Rein Therapeutics Wins U.K. Approval to Launch Phase 2 Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis - GlobeNewswire
UK regulator approves Rein Therapeutics’ phase 2 trial for IPF drug - Investing.com Canada
Identifying reversal signals in Rein Therapeutics Inc.Market Activity Summary & Real-Time Sentiment Analysis - Newser
Rein Therapeutics' Strategic Path Forward: Navigating Clinical and Funding Challenges in a High-Stakes Biotech Landscape - AInvest
Rein Therapeutics Shares Lower After Brookline Capital Downgrade - MarketScreener
Order flow analysis tools used on Rein Therapeutics Inc.July 2025 Intraday Action & Daily Oversold Bounce Ideas - Newser
Multi factor analysis applied to Rein Therapeutics Inc.CEO Change & Weekly Watchlist for Hot Stocks - Newser
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders - 富途牛牛
Combining price and volume data for Rein Therapeutics Inc.July 2025 Intraday Action & Community Trade Idea Sharing - Newser
Brookline Capital Downgrades Rein Therapeutics to Hold From Buy - MarketScreener
Using RSI to spot recovery in Rein Therapeutics Inc.Price Action & Daily Oversold Stock Bounce Ideas - Newser
Rein Therapeutics Inc.’s volatility index tracking explainedJuly 2025 Action & AI Enhanced Trading Signals - Newser
Published on: 2025-08-19 03:47:21 - Newser
Is Rein Therapeutics Inc. forming a reversal patternGap Down & Entry and Exit Point Strategies - Newser
What to expect from Rein Therapeutics Inc. in the next 30 daysJuly 2025 Gainers & Precise Buy Zone Identification - Newser
Heatmap analysis for Rein Therapeutics Inc. and competitorsShare Buyback & Accurate Entry and Exit Point Alerts - Newser
Chart based exit strategy for Rein Therapeutics Inc.Quarterly Earnings Summary & Stepwise Entry/Exit Trade Alerts - Newser
Top chart patterns to watch in Rein Therapeutics Inc.2025 Trading Recap & AI Forecasted Entry/Exit Points - Newser
Published on: 2025-08-17 16:12:16 - Newser
What technical models suggest about Rein Therapeutics Inc.’s comebackRate Hike & Consistent Income Trade Ideas - Newser
Is Rein Therapeutics Inc. a Top Dividend Stock to Watch in 2025July 2025 Reactions & Technical Pattern Recognition Alerts - metal.it
Intraday pattern recognizer results for Rein Therapeutics Inc.Quarterly Trade Summary & Real-Time Sentiment Analysis - Newser
What makes Rein Therapeutics Inc. stock price move sharply2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - Newser
Fibonacci Support Holding Strong in Rein Therapeutics Inc.July 2025 Pullbacks & Risk Controlled Swing Alerts - 선데이타임즈
Earnings visualization tools for Rein Therapeutics Inc.2025 Earnings Surprises & Low Risk Entry Point Guides - Newser
How sentiment analysis helps forecast Rein Therapeutics Inc.M&A Rumor & Risk Managed Investment Entry Signals - Newser
Rein Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Rein Therapeutics to Present Novel IPF Science and Clinical Development Insights at IPF Summit 2025 - GlobeNewswire
Rein Therapeutics Inc Stock (RNTX) Financials Data
There is no financial data for Rein Therapeutics Inc (RNTX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):